Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2017 | Pages:
70 | Publisher: RNCOS
Industry: Healthcare | Report Format: Electronic (PDF)
Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most common type of liver cancer. Most cases of HCC result either from infection with viral hepatitis (Hepatitis B or C), metabolic toxins such as alcohol or aflatoxin, conditions such as hemochromatosis and alpha-deficiency 1-antitrypsin, or NASH. As per RNCOS report “Global Hepatocellular Carcinoma Drug Sales (Nexavar & Miripla), Pipeline Analysis and Global Market Forecast 2022” the global hepatocellular carcinoma drug market is anticipated to witness a remarkable growth in the coming years. The report provides insights about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities for the growth of the Global Hepatocellular Carcinoma Market. Key factors supporting the growth of the global hepatocellular carcinoma market include increasing incidences of chronic diseases like infection with hepatitis B or C virus, diabetes, obesity, non-alcoholic fatty liver diseases, and others. Moreover, the growing aging population, adoption of sedentary lifestyle, and increasing R&D investments are also adding up to the growth of global hepatocellular carcinoma market. However, drug failures in pipeline and stringent regulatory challenges are expected to hamper the growth of the global hepatocellular carcinoma drug market. Furthermore, in this report we have structured the information regarding hepatocellular drugs at various stages of clinical development, totaling to over 350 drugs that are under research or in collaboration and those individually being developed by companies. Out of which, 102 drugs are being developed by industries and rest of the drugs are developed by the research collaborations. The report also provides the segmentation of hepatocellular carcinoma drugs under clinical development on the basis of clinical phase. As per our research, Nexavar is the only approved targeted drug for the advance hepatocellular carcinoma as of now; with the exception of Miripla approved only in Japan. However, there are molecules in the Phase III clinical development as first-line and second-line treatments, promising to influence the competitive landscape over the next two to three years. Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America is accounted for the largest share. In addition, Asia-Pacific is projected to be the fastest growing region due to the increasing incidence of chronic disorders, such as cancer, diabetes, hepatitis infections, and others. Moreover, the report also highlights various mergers and acquisitions taking place in the global hepatocellular carcinoma drug market. The last section of the report discusses about the prominent players in global hepatocellular carcinoma drug market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hepatocellular carcinoma drug market.
Table Of Content
1. Analyst View
2. Research Methodology
3. Hepatocellular Carcinoma- An Introduction
3.1 Etiology and Epidemiology of Hepatocellular Carcinoma
3.2 Risk Factors
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Incidences of Chronic Liver Diseases
4.1.2 Increasing Aging Population
4.1.3 Increasing R&D Investments
4.2 Challenges
4.2.1 Unsuccessful Clinical Trials
4.2.2 Stringent Regulatory Challenges
4.3 Opportunities
4.3.1 Advancement of Cancer Drug Research
4.3.2 Personalized Drug
5. Global Hepatocellular Carcinoma Drug Market Outlook 2022
6. Global Hepatocellular Carcinoma Drug Pipeline Analysis
6.1 Hepatocellular Carcinoma Drug Pipeline by Industries
6.1.1 By Clinical Phase
6.2 Hepatocellular Carcinoma Drug Pipeline by Research and Collaborations
6.2.1 By Clinical Phase
7. Market Segment by Geography
7.1 North America
7.2 Europe
7.3 Asia Pacific
8. Company Profiles
8.1 Pfizer Inc.
8.2 Eli Lilly and Company
8.3 Alnylam Pharmaceuticals, Inc.
8.4 Exelixis, Inc.
8.5 ArQule, Inc.
8.6 Polaris Pharmaceuticals, Inc. (PPI)
8.7 Bayer AG
8.8 Teva Pharmaceutical Industries Ltd.
8.9 Bristol-Mayers Squibb
8.10 Celsion, Inc.
List of Tables: Table 5-1: Global - Drugs with Orphan Drugs Status for Hepatocellular Carcinoma Table 6-1: Global - Hepatocellular Carcinoma Drug in Pipeline by Companies Table 6-2: Global - Hepatocellular Carcinoma Drug in Pipeline by Research Organization Table 8-1: Pfizer Inc. - Financials (Million US$), 2014-2016 Table 8-2: Eli Lilly and Company - Financials (Billion US$), 2014-2016 Table 8-3: Alnylam Pharmaceuticals, Inc. - Financials (Billion US$), 2014-2016 Table 8-4: Exelixis, Inc. - Financials (Billion US$), 2014-2016 Table 8-5: Arqule - Financials (Billion US$), 2014-2016 Table 8-6: Bayer AG - Financials (Million US$), 2014-2016 Table 8-7: Teva Pharmaceutical Industries ltd. - Financials (Million US$), 2014-2016 Table 8-8: Bristol-Mayers Squibb - Financials (Billion US$), 2014-2016 List of Figures: Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050 Figure 5-1: Global - Hepatocellular Carcinoma Drug Market, (Billion US$), 2016 & 2022 Figure 6-1: Global - Hepatocellular Carcinoma Companies Drug Pipeline, by Clinical Phase, (%) 2016 Figure 6-2: Global - Hepatocellular Carcinoma Research Organization Drug Pipeline by Clinical Phase, (%), 2016 Figure 7-1: Global - Hepatocellular Carcinoma Drug Market by Geography (%), 2016 Figure 7-2: North America - Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022 Figure 7-3: Europe - Global Hepatocellular Carcinoma Market (Billion US$), 2016 & 2022 Figure 7-4: Asia Pacific - Hepatocellular Carcinoma Drug Market (Billion US$), 2016 & 2022 Figure 8-1: Pfizer Inc. - Revenue by Business Segments (%), 2016 Figure 8-2: Pfizer Inc. - Revenue by Geography (%), 2016 Figure 8-3: Eli Lilly and Company - Revenue by Business Segments (%), 2016 Figure 8-4: Eli Lilly and Company - Revenue by Geography (%), 2016 Figure 8-5: Bayer AG - Revenue by Business Segments (%), 2016 Figure 8-6: Bayer AG - Revenue by Geography (%), 2016 Figure 8-7: Teva Pharmaceutical Industries Ltd. - Revenue by Business Segments (%), 2016 Figure 8-8: Teva Pharmaceutical industries Ltd. - Revenue by Geography (%), 2016 Figure 8-9: Bristol-Mayers Squibb - Revenue by Geography (%), 2016
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
